Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106295 · ClinicalTrials.gov registry record · Phase 2
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
A Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06106295 is a Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06106295, a Phase 2 study of Mild Autonomous Cortisol Secretion (MACS) and Autonomous Cortisol Secretion, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
Conditions Studied
Interventions
- DRUG Metyrapone
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106295
The ClinicalTrials.gov registry entry for NCT06106295 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Autonomous Cortisol Secretion (MACS) appearing as the primary indexed condition, and to 1 intervention - of which Metyrapone is the first listed.
NCT06106295 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06106295 about?
NCT06106295 is a clinical study titled "Metyrapone for Mild Autonomous Cortisol Secretion (MACS)". The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
What is the current status of trial NCT06106295?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-12-19. Estimated completion is 2028-02-01.
What conditions does trial NCT06106295 study?
This clinical trial studies the following conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion.
What interventions are being tested in trial NCT06106295?
The interventions under investigation include: Metyrapone (DRUG).
Who is sponsoring clinical trial NCT06106295?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106295 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Autonomous Cortisol Secretion (MACS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Mild Autonomous Cortisol Secretion (MACS)
All registered trials for this condition
Autonomous Cortisol Secretion
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.